Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): A 3-month, double-masked, randomised, placebo-controlled trial

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 244, Issue 5, 2006, Pages 551-558

  Wilhelm, Barbara ^a   Lüdtke, Holger ^a   Wilhelm, Helmut ^b   Gamer, Daphne ^c   Knappe, Steffi ^c   Vick, Hans Peter ^c   Schmid, Rüdiger ^c   Charberl Issa, Peter ^c   Schrader, Wolfgang ^c   Wilhelm, Frank ^c   Ehrich, Dirk ^c   Rüther, Klaus ^c   Scherer, Matthias ^c   Müller, Bert ^c   Kuhli, Claudia ^c   Zubcov, Alina ^c   Wiese, Stefan ^c   Lagrèze, Wolf ^c   Kuchenbecker, Jörn ^c   Gottlob, Irene ^c   Langerhorst, Christine ^c   more..

^a Steinbeis Transfer Centre for Biomedical Optics and Function Testing (STC)   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c NONE

Author keywords

AION; Anterior ischemic optic neuropathy; Brimonidine; Neuroprotection

Indexed keywords

BRIMONIDINE; PLACEBO;

ACUTE DISEASE; ADULT; ARTICLE; AUTOMATION; BILIARY COLIC; BRONCHITIS; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EUROPE; EYE INFLAMMATION; EYE IRRITATION; FEASIBILITY STUDY; FEMALE; GOOD CLINICAL PRACTICE; HUMAN; HYPOGLYCEMIA; ISCHEMIC OPTIC NEUROPATHY; MALE; MULTICENTER STUDY; OPEN STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RETINA VEIN OCCLUSION; RETROSPECTIVE STUDY; SEX DIFFERENCE; STATISTICAL ANALYSIS; STUDENT T TEST; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL FIELD; VISUAL IMPAIRMENT; XEROSTOMIA;

ACUTE DISEASE; AGED; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OPTIC NEUROPATHY, ISCHEMIC; QUINOXALINES; TIME FACTORS; TREATMENT OUTCOME; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 33646770618     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-005-0102-8     Document Type: Article

References (27)

1. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D (2002) Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos 30(4):421-429
2. Acheampong AA, Shackleton M, Tang-Liu DD (1995) Comparative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 23(7):708-12
3. Beck RW, Hayreh SS (2000) Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye 14(Pt 1):118
4. Fazzone HE, Kupersmith MJ, Leibmann J (2003) Does topical brimonidine tartrate help NAION? Br J Ophthalmol 87(9):1193-1194
5. Haas A, Uyguner I, Sochor GE, Schmut O, Vidic B, Faulborn J (1994) Nichtarteriitische vordere ischämische Optikusneuropathie: Langzeitergebnisse nach Hämodilutionstherapie. Klin Monatsbl Augenheilkd 205(3):143-146
6. Hayreh SS (2000) Ischaemic optic neuropathy. Ind J Ophthalmol 48(3):171-194
7. Ischemic Optic Neuropathy Decompression Trial Research Group (1995) Optic nerve decompression surgery for non-ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 273:625-632
8. Johnson LN, Guy ME, Krohel GB, Madsen RW (2000) Levodopa may improve vision loss in recentonset, nonarteritic anterior ischemic optic neuropathy. Ophthalmology 107(3):521-526
9. Kelman SE (1998) Ischemic optic neuropathies. In: Miller NR, Newman WD (eds) Walsh and Hoyt's clinical neuro-ophthalmology, vol. 1. Williams and Wilkins, Baltimore, pp 549-598
10. Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D (2001) Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology 108(4):784-787
11. Kline LB (1988) Progression of visual field defects in ischemic optic neuropathy. Am J Ophthalmol 106:199-203
12. Kupersmith MJ, Frohman L, Sanderson M, Jacobs J, Hirschfeld J, Ku C, Warren FA (1997) Aspirin reduces the incidence of second eye NAION: A retrospective study. J Neuro-Ophthalmol 17(4):250-253
13. Lai RK, Chun T, Hasson D, Lee S, Mehrbrod F, Wheeler L (2002) Alpha-2-adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci 19(2):175-185
14. Levkovitch-Verbin H, Harris-Cerruti C, Groner Y, Wheeler LA, Schwartz M, Yoles E (2000) RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci 41(13):4169-4174
15. Menzi J, Körner F (1992) Systemische Kortikosteroidtherapie bei nicht-arteriitischer anteriorer ischämischer Optikusneuropathie. Klin Monatsbl Augenheilkd 200(5):349-353
16. Slavin ML, Margolis AJ (1988) Progressive anterior ischemic optic neuropathy due to giant cell arteritis despite high-dose intravenous corticosteroids. Arch Ophthalmol 106(9):1167
17. Swartz NG, Beck RW, Savino PJ, Sergott RC, Bosley TM, Lam BL, Drucker M, Katz B (1995) Pain in anterior ischemic optic neuropathy. J Neuroophthalmol 15(1):9-10
18. Trobe JD (2001) The neurology of vision. Oxford University Press, New York
19. Weber J, Schiefer U, Kolling G (2004) Proposed scoring system for assessment of functional impairment due to visual field defects. Der Ophthalmologe 101:1030-1033 1030-1033
20. Wheeler L, WoldeMussie E, Lai R (2003) Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 48(Suppl 1):S47-S51
21. Wheeler LA, Gil DW, WoldeMussie E (2001) Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol 45(Suppl 3):S290-S294; discussion S295-296
22. Wheeler LA, Lai R, Woldemussie E (1999) From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 9(Suppl 1):S17-S21
23. Wheeler LA, Woldemussie E (2001) Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma. Eur J Ophthalmol 11(Suppl 2):S30-S35
24. Wilhelm B, Lüdtke H, Peters T, Schmid R, Wilhelm H, Zrenner E (2001) Automatisierter Swinging-flashlight-Test bei Patienten mit Sehnervenerkrankungen. Klin Monatsbl Augenheilkd 218(1):21-25
25. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA (2001) Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 42(12):2849-2855
26. Wolf S, Schulte-Strake U, Bertram B, Schulte K, Arend O, Reim M (1993) Hämodilutionstherapie bei Patienten mit akuter vorderer ischämischer Optikusneuropathie. Ophthalmologe 90(1):21-26
27. Yoles E, Wheeler LA, Schwartz M (1999) Alpha2-adrenoreceptor agonists are neuroprotective in a rat model of optic nerve degeneration. Invest Ophthalmol Vis Sci 40(1):65-73